Osiris Therapeutics (OSIR) was notified that its PROCHYMAL received FDA ‘Fast Track’designation, expediting thedevelopment of the stem cell treatment for Crohn’s Disease that fails to respond to standard therapies. This takes it to Phase III clinical trials, which will be the last trial stage prior to seeking FDA Approval if resukts are successful. OSIR shares are up almost 5% at$26.30 in after-hours and shares traded 3-times normal volume; the 52 week trading band is $9.84 to $27.93. OSIR is a recently public company that is up some 150% since the August IPO and its market cap is $685 now million before the after-hours pop. Jefferies just downgraded this on valuation to a Hold last week, so much of this may already be refelcted in today’s prices.
Jon C. Ogg
January 8, 2007
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
